MEI Pharma Inc

NASDAQ:MEIP   12:12:03 PM EDT
1.99
-0.01 (-0.50%)
Products, Regulatory

Mei Pharma And Kyowa Kirin Announce Data From Ongoing Global Phase 2 Tidal Study Evaluating Zandelisib As A Single Agent In Patients With Relapsed Or Refractory Follicular Lymphoma

Published: 11/30/2021 13:04 GMT
MEI Pharma Inc (MEIP) - Mei Pharma and Kyowa Kirin Announce Data From Ongoing Global Phase 2 Tidal Study Evaluating Zandelisib As a Single Agent in Patients With Relapsed Or Refractory Follicular Lymphoma.
Mei Pharma Inc - Zandelisib Demonstrated 70.3% Objective Response Rate; 35.2% Achieved Complete Response.
Mei Pharma Inc - 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event.
Mei Pharma Inc - in Line With Previously Reported Data From Phase 1b Study, Zandelisib Was Generally Well Tolerated.
Mei Pharma Inc - Patients Enrolled in Study Will Continue to Be Followed for Safety and Dor.
Further Company Coverage: 4151.
T.
((reuters.
Briefs@thomsonreuters.
Com;)).